Evidence map›Paper›PMID 33925288›Full record

ReviewMolecules (Basel, Switzerland)2021

Effects of Modifications on the Immunosuppressive Properties of Cyclolinopeptide A and Its Analogs in Animal Experimental Models.

Michał Zimecki, Krzysztof Kaczmarek

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. New Advances in Short Peptides: Looking Forward.Molecules (Basel, Switzerland) · 2022
    Article
  4. Antiviral Activity of a Cyclic Pro-Pro-Molecules (Basel, Switzerland) · 2022
    Article
  5. Advances in Research of Short Peptides.Molecules (Basel, Switzerland) · 2022
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Michał ZimeckiLaboratory of Immunobiology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, R. Weigla Str. 12, 53-114 Wrocław, Poland.
Krzysztof KaczmarekInstitute of Organic Chemistry, Lodz University of Technology, S. Żeromskiego Str. 116, 90-924 Łódź, Poland.ORCID 0000-0001-8806-7792
Lodz University of Technology · PLLudwik Hirszfeld Institute of Immunology and Experimental Therapy · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The consequences of manipulations in structure and amino acid composition of native cyclolinopeptide A (CLA) from linen seeds, and its linear precursor on their biological activities and mechanisms of action, are reviewed. The modifications included truncation of the peptide chain, replacement of amino acid residues with proteinogenic or non-proteinogenic ones, modifications of peptide bond, and others. The studies revealed changes in the immunosuppressive potency of these analogs investigated in a number of in vitro and in vivo experimental models, predominantly in rodents, as well as differences in their postulated mechanism of action. The modified peptides were compared with cyclosporine A and parent CLA. Some of the synthesized and investigated peptides show potential therapeutic usefulness.

Indexed as

Structure-Activity RelationshipAmino Acid SequenceAnimalsBedding and LinensImmunosuppressive AgentsModels, AnimalPeptidesPeptides, CyclicSeedscyclolinopeptide AImmunosuppressive AgentsPeptidesPeptides, Cycliccis-peptide bondcyclolinopeptide A (CLA)cyclosporine Aedge-to-facehomo amino acidsimmunosuppressionPGE2

Identifiers

PMID33925288
PMCPMC8123640
OpenAlexW3136781346

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.